Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16

International Journal of Oncology

Volumn 14, Issue 3, 1999, Pages 593-597

  Bubeník, Jan ^a   Símová, Jana ^a   Hájková, Romana ^a   Sobota, Vesna ^a   Jandlová, Tána ^a   Smahel, Michal ^b   Sobotková, Eva ^b   Vonka, Vladimír ^b  

^a INSTITUTE OF MATHEMATICS   (Czech Republic)

^b INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

HPV 16; Interleukin 2; Tumour vaccines

Indexed keywords

INTERLEUKIN 2;

ANIMAL; ARTICLE; C57BL MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; GENE THERAPY; GENETICS; IMMUNOLOGY; MALE; MINIMAL RESIDUAL DISEASE; MOUSE; PAPILLOMA VIRUS; PATHOGENICITY; VIROLOGY;

ANIMALS; GENE THERAPY; INTERLEUKIN-2; MALE; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASM, RESIDUAL; PAPILLOMAVIRIDAE; TUMOR CELLS, CULTURED;

EID: 0033092207     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.14.3.593     Document Type: Article

References (23)

1. McDougall JK: Immortalization and transformation of human cells by human papillomavirus. Curr Top Microbiol Immunol 186: 101-119, 1994.
2. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R and Shah KV: Prevalence of human papillomavirus in cervical cancer, a worldwide perspective. J Natl Cancer Inst 87: 796-802, 1995.
3. Zur Hausen H: Papillomavirus infections - major cause of human cancer. Biochim Biophys Acta 1288: F55-F58, 1996.
4. Wu TC: Immunology of the human papilloma virus in relation to cancer. Curr Opin Immunol 6: 746-754, 1994.
5. Tindle RW and Frazer IH: Immune response to human papillomaviruses and the prospects for human papillomavirus-specific immunisation. Curr Top Microbiol Immunol 186: 217-253, 1994.
6. Jochmus J and Gissmann L: Immunological aspects of the E6 and E7 oncogenes: tools for diagnosis and therapeutic intervention. In: Papillomaviruses in Human Cancer: The Role of E6 and E7 Oncoproteins. Tomassino M (ed). Landes Bioscience, New York, pp137-165, 1997.
7. De Bruijn MLH, Schuurhuis DH, Vierboom MPM, Vermeulen H, De Cock KAJ, Ooms ME, Ressing ME, Toebes M, Franken KLMC, Drijfhout JW, Ottenhoff THM, Offringa R and Melief CJM: Immunization with human papillomavirus type 16 (HPV 16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV 16-induced tumor cells. Cancer Res 58: 724-731, 1998.
8. Bubeník J, Símová J and Jandlová T: Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2. Immunol Lett 23: 287-292, 1989/1990.
9. Bubeník J, Rössner P, Bubeníková D, Símová J, Indrová M and Sloncová E: Tumour vaccines expressing IL-2, CD80, and IL-2 plus CD80 gene. Int J Oncol 11: 1213-1219, 1997.
10. Vlk V, Rössner P, Indrová M, Bubeník J and Sobota V: Interleukin-2 gene therapy of surgical minimal residual tumour disease. Int J Cancer 76: 115-119, 1998.
11. Bubeník J, Indrová M, Nemecková S, Malkovsky M, von Broen B, Pálek V and Anderlíková J: Solubilized tumor-associated antigens of methylcholanthrene-induced mouse sarcomas. Comparative studies by in vitro sensitization of lymph node cells, macrophage electrophoretic mobility assay and transplantation test. Int J Cancer 21: 348-355, 1978.
12. Rössner P, Bubeník J, Indrová M, Sobota V, Vondrys P, Zeuthen J, Jandlová T and Takác M: Genetically modified tumour vaccines: insertion of the IL-2 gene downregulates tumorigenicity more efficiently than insertion of the CD80 gene. Int J Oncol 10: 77-82, 1997.
13. Kearney JF, Radbruch A, Liesegang B and Rajewsky K: A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol 123: 1548-1550, 1979.
14. Karasuyama H and Melchers F: Establishment of mouse cell lines which constitutively secrete large quantities of interleukin-2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol 18: 97-104, 1988.
15. Kitasato H, Vonka R, Bostík P, Hamsíková E, Sobotková E, Smahel M and Vonka V: Properties of Syrian hamster cells transformed by human papillomavirus type 16. Acta Virol 40: 281-288, 1996.
16. Sarmiento M, Glasebrook AL and Fitch FW: IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. J Immunol 125: 2665-2672, 1980.
17. Símová J, Bubeník J, Jandlová T and Indrová M: Irradiated IL-2 gene-modified plasmacytoma vaccines are more efficient than live vaccines. Int J Oncol 12: 1195-1198, 1998.
18. Bubeník J, Símová J, Bubeníková D, Zeuthen J and Indrová M: Interleukin-2 gene therapy of residual EL-4 leukaemia potentiates the effect of cyclophosphamide pretreatment. J Cancer Res Clin Oncol 121: 39-43, 1995.
19. Thomas MC, Greten TF, Pardoll DM and Jaffee EM: Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum Gene Ther 9: 835-843, 1998.
20. Zinkernagel RM: Immunology taught by viruses. Science 271: 173-178, 1996.
21. Quintin-Colona F, Devauchelle P, Fradelizi D, Mourot B, Faure T, Kourilsky P, Roth C and Mehtali M: Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2. Gene Ther 3: 1104-1112, 1996.
22. Fleischmann D and Kim B: Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma. J Urol 145: 938-941, 1991.
23. Brivio F, Lissoni AG, Alderi G, Barni S, Lavorato F and Fumagalli L: Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients. Oncology 53: 263-268, 1996.